Web Exclusives
In a single-arm, single-institution study, combining pembrolizumab, bevacizumab, and metronomic oral cyclophosphamide led to a median progression-free survival of 10 months in women with recurrent ovarian cancer, with better response in women with platinum-sensitive disease. Read More ›
An online educational tool about PARP inhibitors improved clinicians’ confidence in their ability to use them correctly in women with newly diagnosed advanced ovarian cancer. Read More ›
Establishing protocols for side-effect reporting and management beforehand can maximize adherence to PARP inhibitor maintenance therapy. Read More ›
Although the combination of bevacizumab and olaparib showed superior progression-free survival compared with bevacizumab plus placebo as upfront maintenance therapy in women with advanced ovarian cancer, the lack of an olaparib monotherapy comparator limits meaningful interpretation. Read More ›
The rate of overall survival was similar between nivolumab and either gemcitabine or pegylated liposomal doxorubicin in the open-label, randomized phase 3 NINJA clinical trial of patients with platinum-resistant ovarian cancer, but the overall duration of response was longer in the nivolumab arm. Read More ›
In the FORWARD II clinical trial, mirvetuximab soravtansine combined with carboplatin and bevacizumab induced an overall response rate of 83% in patients with recurrent platinum-sensitive ovarian cancer. Read More ›
Copay maximizer programs are replacing copay accumulator programs, and the trend toward increasing cost burden for patients continues. Read More ›
The combination of dabrafenib and trametinib performs as well in the real world as in clinical trials in patients with BRAF V600-mutated advanced melanoma and brain metastases, but the medical need for patients with brain metastases remains high. Read More ›
The combination of ipilimumab and anti–PD-1 therapy showed efficacy comparable to clinical trial populations in patients with preexisting autoimmune disease and advanced melanoma. Read More ›
A review of posts to health-related social media over a 5-year period reveals that symptoms and their impact are the most frequently discussed topics by patients with melanoma and their caregivers. Read More ›